Short Interest in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Increases By 17.5%

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 8,000,000 shares, an increase of 17.5% from the December 15th total of 6,810,000 shares. Currently, 21.1% of the shares of the company are sold short. Based on an average daily volume of 1,410,000 shares, the short-interest ratio is presently 5.7 days.

Analyst Upgrades and Downgrades

CKPT has been the topic of a number of analyst reports. Lake Street Capital raised their price objective on shares of Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. D. Boral Capital initiated coverage on shares of Checkpoint Therapeutics in a research report on Monday, January 13th. They set a “buy” rating and a $9.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Checkpoint Therapeutics in a research report on Monday, December 16th.

Checkpoint Therapeutics Trading Down 4.5 %

Shares of CKPT stock traded down $0.15 during trading hours on Friday, hitting $3.18. 592,705 shares of the company’s stock were exchanged, compared to its average volume of 2,262,361. Checkpoint Therapeutics has a fifty-two week low of $1.38 and a fifty-two week high of $4.50. The firm has a 50 day moving average of $3.62 and a two-hundred day moving average of $2.91.

Checkpoint Therapeutics (NASDAQ:CKPT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). On average, equities research analysts expect that Checkpoint Therapeutics will post -0.91 EPS for the current fiscal year.

Insider Buying and Selling

In other Checkpoint Therapeutics news, CEO James F. Oliviero III sold 220,230 shares of the stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $3.38, for a total transaction of $744,377.40. Following the sale, the chief executive officer now directly owns 3,194,583 shares of the company’s stock, valued at approximately $10,797,690.54. This trade represents a 6.45 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO William Garrett Gray sold 268,432 shares of the business’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $4.01, for a total value of $1,076,412.32. Following the completion of the transaction, the chief financial officer now directly owns 1,032,754 shares of the company’s stock, valued at approximately $4,141,343.54. This trade represents a 20.63 % decrease in their position. The disclosure for this sale can be found here. 2.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new stake in Checkpoint Therapeutics during the 3rd quarter worth approximately $30,000. XTX Topco Ltd acquired a new stake in shares of Checkpoint Therapeutics in the second quarter worth approximately $34,000. Bartlett & CO. Wealth Management LLC increased its position in shares of Checkpoint Therapeutics by 375.0% during the fourth quarter. Bartlett & CO. Wealth Management LLC now owns 19,000 shares of the company’s stock worth $61,000 after purchasing an additional 15,000 shares in the last quarter. Gladstone Institutional Advisory LLC raised its stake in Checkpoint Therapeutics by 141.4% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock valued at $78,000 after purchasing an additional 20,500 shares during the last quarter. Finally, Magnus Financial Group LLC lifted its holdings in Checkpoint Therapeutics by 12.9% in the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after purchasing an additional 4,000 shares in the last quarter. 22.00% of the stock is owned by hedge funds and other institutional investors.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.